Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased cost

Liver Transplantation

Volumn 15, Issue 2, 2009, Pages 148-162

  Northup, Patrick G ^a,f   Abecassis, Michael M ^b   Englesbe, Michael J ^c   Emond, Jean C ^d   Lee, Vanessa D ^a   Stukenborg, George J ^a,e   Tong, Lan ^c   Berg, Carl L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d Columbia University College of Physicians and Surgeons ^*  (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CADAVER DONOR; CHRONIC LIVER DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; GRAFT RECIPIENT; HEALTH CARE COST; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVING DONOR; MONTE CARLO METHOD; MORBIDITY; MORTALITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; SENSITIVITY ANALYSIS; SIMULATION; SURVIVAL RATE; VALIDATION PROCESS;

ADULT; COHORT STUDIES; COST-BENEFIT ANALYSIS; DECISION TREES; FEMALE; HUMANS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS; WAITING LISTS;

EID: 67649215739     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21671     Document Type: Article

References (128)

1. Hashikura Y, Kawasaki S, Terada M, Ikegami T, Nakazawa Y, Urata K, et al. Long-term results of living-related donor liver graft transplantation: a single-center analysis of 110 transplants. Transplantation 2001;72:95-99.
2. Fujita S, Kim ID, Uryuhara K, Asonuma K, Egawa H, Kiuchi T, et al. Hepatic grafts from live donors: donor morbidity for 470 cases of live donation. Transpl Int 2000;13:333-339.
3. Ghobrial R, Freise C, Trotter J, Tong L, Ojo A, Fair J, et al. Donor morbidity and mortality of adult living donors for liver transplantation [abstract]. Am J Transpl 2006;6: (suppl 2):115.
4. Azoulay D, Linhares MM, Huguet E, Delvart V, Castaing D, Adam R, et al. Decision for retransplantation of the liver: an experience- and cost-based analysis. Ann Surg 2002;236:713-721; discussion 721.
5. Bonsel GJ, Klompmaker IJ, Essink-Bot ML, Habbema JD, Slooff MJ. Cost-effectiveness analysis of the Dutch liver transplantation programme. Transplant Proc 1990; 22:1481-1484.
6. Freeman R, Tsunoda S, Supran S, Warshaw A, Smith J, Fairchild R, et al. Direct costs for one year of liver transplant care are directly associated with disease severity at transplant. Transplant Proc 2001;33:1436-1437.
7. Kam I. Cadaveric versus living donor liver transplantation - analysis of costs. Transplant Proc 2003;35:971.
8. Trotter JF, Mackenzie S, Wachs M, Bak T, Steinberg T, Polsky P, et al. Comprehensive cost comparison of adult-adult right hepatic lobe living-donor liver transplantation with cadaveric transplantation. Transplantation 2003;75:473-476.
9. Filipponi F, Pisati R, Ferrara R, Mosca F. Cost and outcome evaluation of liver transplantation at Cisanello Hospital: (2). Results. Transplant Proc 2003;35:1041-1044.
10. Buell JF, Cronin DC, Blahnik L, Lo A, Trimbach C, Layman R, et al. The impact of donor factors on the outcomes following liver transplantation. Transplant Proc 2002;34: 1495-1496.
11. Chen CL, Fan ST, Lee SG, Makuuchi M, Tanaka K. Living-donor liver transplantation: 12 years of experience in Asia. Transplantation 2003;75(suppl):S6-S11.
12. Seaman DS. Adult living donor liver transplantation: current status. J Clin Gastroenterol 2001;33:97-106.
13. Belle SH, Porayko MK, Hoofnagle JH, Lake JR, Zetterman RK. Changes in quality of life after liver transplantation among adults. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Liver Transplantation Database (LTD). Liver Transplant Surg 1997;3:93-104.
14. De Bona M, Ponton P, Ermani M, Iemmolo RM, Feltrin A, Boccagni P, et al. The impact of liver disease and medical complications on quality of life and psychological distress before and after liver transplantation. J Hepatol 2000;33: 609-615.
15. Gross CR, Malinchoc M, Kim WR, Evans RW, Wiesner RH, Petz JL, et al. Quality of life before and after liver transplantation for cholestatic liver disease. Hepatology 1999;29:356-364.
16. Karam V, Castaing D, Danet C, Delvart V, Gasquet I, Adam R, et al. Longitudinal prospective evaluation of quality of life in adult patients before and one year after liver transplantation. Liver Transpl 2003;9:703-711.
17. Karam VH, Gasquet I, Delvart V, Hiesse C, Dorent R, Danet C, et al. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation 2003;76:1699-1704.
18. Moore KA, Mc LJR, Burrows GD. Quality of life and cognitive function of liver transplant patients: a prospective study. Liver Transpl 2000;6:633-642.
19. Moore D, Feurer I, Speroff T, Shaffer D, Nylander W, Kizilisik T, et al. Survival and quality of life after organ transplantation in veterans and nonveterans. Am J Surg 2003;186:476-480.
20. Morimoto T, Yamaoka Y, Tanaka K, Ozawa K. Quality of life among donors of liver transplants to relatives. N Engl J Med 1993;329:363-364.
21. Pinson CW, Feurer ID, Payne JL, Wise PE, Shockley S, Speroff T. Health-related quality of life after different types of solid organ transplantation. Ann Surg 2000;232: 597-607.
22. Ratcliffe J, Longworth L, Young T, Bryan S, Burroughs A, Buxton M, et al. Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study. Liver Transpl 2002;8:263-270.
23. Saab S, Ly D, Han SB, Lin RK, Rojter SE, Ghobrial RM, et al. Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients? Liver Transpl 2002;8:449-457.
24. Cheng SJ, Pratt DS, Freeman RB Jr, Kaplan MM, Wong JB. Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis. Transplantation 2001;72:861-868.
25. Sagmeister M, Mullhaupt B, Kadry Z, Kullak-Ublick GA, Clavien PA, Renner EL. Cost-effectiveness of cadaveric and living-donor liver transplantation. Transplantation 2002;73:616-622.
26. Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and cost-effectiveness perspective. Hepatology 2001;33:1073-1079.
27. National Institutes of Health. Adult-to-Adult Living Donor Liver Transplantation Cohort Study. Available at: http://www.nih-a2all.org. Accessed October 2008.
28. Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL). Hepatology 2003;38:792.
29. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-338.
30. Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. JAMA 1989;262: 2879-2886.
31. Olthoff KM, Merion RM, Ghobrial RM, Abecassis MM, Fair JH, Fisher RA, et al. Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL consortium. Ann Surg 2005;242:314-323; discussion 323-315.
32. Organ Procurement and Transplantation Network. Standard transplant analysis and research database. Available at: http://www.optn.org. Accessed October 2008.
33. University of Virginia Clinical Data Repository. Available at: http://www.med.virginia.edu/cdr. Accessed October 2008.
34. Pates RD, Scully KW, Einbinder JS, Merkel RL, Stukenborg GJ, Spraggins TA, et al. Adding value to clinical data by linkage to a public death registry. Medinfo 2001; 10(pt2): 1384-1388.
35. Einbinder JS, Scully KW, Pates RD, Schubart JR, Reynolds RE. Case study: a data warehouse for an academic medical center. J Healthcare Inf Manag 2001;15:165-175.
36. Scully KW, Pates RD, Desper GS, Connors AF, Harrell FE Jr, Pieper KS, et al. Development of an enterprise-wide clinical data repository: merging multiple legacy databases. Proc AMIA Annu Fall Symp 1997:32-36.
37. Northup PG, Berg CL. Cost minimization in endoscopy center scheduling: a case-controlled study. J Clin Gastroenterol 2005;39:268-272.
38. Arseneau KO, Cohn SM, Cominelli F, Connors AF Jr. Cost-utility of initial medical management for Crohn's disease perianal fistulae [see comment]. Gastroenterology 2001;120:1640-1656.
39. Froberg DG, Kane RL. Methodology for measuring health-state preferences - II: scaling methods. J Clin Epidemiol 1989;42:459-471.
40. Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 2001;96:579-583.
41. Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98:630-638.
42. Rubenstein JH, Eisen GM, Inadomi JM. A cost-utility analysis of secondary prophylaxis for variceal hemorrhage. Am J Gastroenterol 2004;99:1274-1288.
43. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127: 855-865.
44. Stein K, Rosenberg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut 2002;50:253-258.
45. Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997;127:866-874.
46. Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998;280:2088-2093.
47. Bryce CL, Angus DC, Switala J, Roberts MS, Tsevat J. Health status versus utilities of patients with end-stage liver disease. Qual Life Res 2004;13:773-782.
48. Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005;3:75-84.
49. Valentin-Gamazo C, Malago M, Karliova M, Lutz JT, Frilling A, Nadalin S, et al. Experience after the evaluation of 700 potential donors for living donor liver transplantation in a single center. Liver Transpl 2004;10:1087-1096.
50. Trotter JF, Wachs M, Trouillot T, Steinberg T, Bak T, Everson GT, et al. Evaluation of 100 patients for living donor liver transplantation. Liver Transpl 2000;6:290-295.
51. Trotter JF, Wachs M, Everson GT, Kam I. Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med 2002;346:1074-1082.
52. Marcos A. Right-lobe living donor liver transplantation. Liver Transpl 2000;6(suppl 2):S59-S63.
53. Broelsch CE, Malago M, Testa G, Valentin Gamazo C. Living donor liver transplantation in adults: outcome in Europe. Liver Transpl 2000;6(suppl 2):S64-S65.
54. Todo S, Furukawa H, Jin MB, Shimamura T. Living donor liver transplantation in adults: outcome in Japan. Liver Transpl 2000;6(suppl 2):S66-S72.
55. Renz JF, Roberts JP. Long-term complications of living donor liver transplantation. Liver Transpl 2000;6(suppl 2):S73-S76.
56. Morbidity after live donor hepatectomy based on Clavien scoring. Transplantation 2006;82(suppl 2):116.
57. Tamura S, Sugawara Y, Kaneko J, Yamashiki N, Kishi Y, Matsui Y, et al. Systematic grading of surgical complications in live liver donors according to Clavien's system. Transpl Int 2006;19:982-987.
58. Gazelle GS, Hunink MG, Kuntz KM, McMahon PM, Halpern EF, Beinfeld M, et al. Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis. Ann Surg 2003;237:544-555.
59. Berg CL. Living donor liver transplantation reduces the risk of death of transplant candidates. Paper presented at: 55th Annual Meeting of the American Association for the Study of Liver Diseases; October 31, 2004; Boston, MA.
60. Berg CL, Gillespie BW, Merion RM, Brown RS Jr, Abecassis MM, Trotter JF, et al. Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology 2007;133:1806-1813.
61. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant 2005;5:307-313.
62. Bambha K, Kim WR. Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls. Eur J Gastroenterol Hepatol 2004;16:519-526.
63. Wagner JL, Herdman RC, Wadhwa S. Cost effectiveness of colorectal cancer screening in the elderly. Ann Intern Med 1991;115:807-817. javascript:PopUp Menu2_Set(Menu1929029)
64. Johannesson M. The cost-effectiveness of the switch towards more expensive antihypertensive drugs. Health Policy 1994;28:1-13.
65. Johannesson M. The impact of age on the cost-effectiveness of hypertension treatment: an analysis of randomized drug trials. Med Decis Making 1994;14:236-244.
66. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251-259.
67. Spiegel BM, Dulai GS, Lim BS, Mann N, Kanwal F, Gralnek IM. The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage. Clin Gastroenterol Hepatol 2006;4: 988-997.
68. Hornberger JC. The hemodialysis prescription and cost effectiveness. Renal Physicians Association Working Committee on Clinical Guidelines. J Am Soc Nephrol 1993;4:1021-1027.
69. Rodriguez-Carmona A, Perez Fontan M, Bouza P, Garcia Falcon T, Valdes F. The economic cost of dialysis: a comparison between peritoneal dialysis and in-center hemodialysis in a Spanish unit. Adv Perit Dial 1996;12:93-96.
70. Tousignant P, Guttmann RD, Hollomby DJ. Transplantation and home hemodialysis: their cost-effectiveness. J Chronic Dis 1985;38:589-601.
71. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000;20:332-342.
72. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004;350:1646-1654.
73. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003;38:258-266.
74. Russo MW, Sood A, Jacobson IM, Brown RS Jr. Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality. Am J Gastroenterol 2003;98:2521-2527.
75. Rimola A, Garcia-Tsao G, Navasa M, Piddock LJV, Planas R, Bernard B, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol 2000;32:142-153.
76. Garcia-Tsao G. Spontaneous bacterial peritonitis. Gastroenterol Clin North Am 1992;21:257-275.
77. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993;18: 353-358.
78. Pinzello G, Simonetti R, Camma C, Dino O, Milazzo G, Pagliaro L, et al. Spontaneous bacterial peritonitis: an update. Gastroenterol Int 1993;6:54-60.
79. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruizdel-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341:403-409.
80. Jalan R, Hayes PC. Hepatic encephalopathy and ascites. Lancet 1997;350:1309-1315.
81. Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999; 30:890-895.
82. Forrest EH, Stanley AJ, Redhead DN, McGilchrist AJ, Hayes PC. Clinical response after transjugular intrahepatic portosystemic stent shunt insertion for refractory ascites in cirrhosis. Aliment Pharmacol Ther 1996;10: 801-806.
83. Figueras J, Jaurrieta E, Valls C, Benasco C, Rafecas A, Xiol X, et al. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology 1997;25:1485-1489.
84. Merion R. SRTR analysis after waitlisting for HCC patients under MELD-based allocation. Paper presented at: OPTN/UNOS Symposium on Liver Allocation Policy for HCC; January 26, 2003; Miami, FL.
85. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22:332-354.
86. Hou MC, Lin HC, Liu TT, Kuo BI, Lee FY, Chang FY, et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 2004;39:746-753.
87. Okano H, Shiraki K, Inoue H, Kawakita T, Deguchi M, Sugimoto K, et al. Long-term follow-up of patients with liver cirrhosis after endoscopic ethanol injection sclerotherapy for esophageal varices. Hepatogastroenterology 2003;50:1556-1559.
88. Sorbi D, Gostout CJ, Peura D, Johnson D, Lanza F, Foutch PG, et al. An assessment of the management of acute bleeding varices: a multicenter prospective member-based study. Am J Gastroenterol 2003;98:2424-2434.
89. Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987;7:122-128.
90. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial [see comment]. Lancet 2002;359:1734-1739.
91. Llovet JM, Fuster J, Bruix J. Prognosis of hepatocellular carcinoma. Hepatogastroenterology 2002;49:7-11.
92. Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002;50:123-128.
93. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35:519-524.
94. Chui AKK, Shi LW, Rao ARN, Anasuya A, Hagl C, Pillay P, et al. Primary graft dysfunction after liver transplantation. Transplant Proc 2000;32:2219-2220.
95. Ploeg RJ, D'Alessandro AM, Knechtle SJ, Stegall MD, Pirsch JD, Hoffmann RM, et al. Risk factors for primary dysfunction after liver transplantation - a multivariate analysis. Transplantation 1993;55:807-813.
96. Singh N, Gayowski T, Wagener MM, Marino IR. Bloodstream infections in liver transplant recipients receiving tacrolimus. Clin Transplant 1997;11:275-281.
97. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Predicting bacteremia and bacteremic mortality in liver transplant recipients. Liver Transpl 2000;6:54-61.
98. Wagener MM, Yu VL. Bacteremia in transplant recipients: a prospective study of demographics, etiologic agents, risk factors, and outcomes. Am J Infect Control 1992;20:239-247.
99. Urbani L, Catalano G, Biancofiore G, Bindi L, Consani G, Bisa M, et al. Surgical complications after liver transplantation. Minerva Chir 2003;58:675-692.
100. O'Connor TP, Lewis WD, Jenkins RL. Biliary tract complications after liver transplantation. Arch Surg 1995; 130:312-317.
101. Sawyer RG, Punch JD. Incidence and management of biliary complications after 291 liver transplants following the introduction of transcystic stenting. Transplantation 1998;66:1201-1207.
102. Baccarani U, Risaliti A, Zoratti L, Zilli M, Brosola P, Vianello V, et al. Role of endoscopic retrograde cholangiopancreatography in the diagnosis and treatment of biliary tract complications after orthotopic liver transplantation [see comment]. Dig Liver Dis 2002;34:582-586.
103. Pfau PR, Kochman ML, Lewis JD, Long WB, Lucey MR, Olthoff K, et al. Endoscopic management of postoperative biliary complications in orthotopic liver transplantation. Gastrointest Endosc 2000;52:55-63.
104. Shah JN, Ahmad NA, Shetty K, Kochman ML, Long WB, Brensinger CM, et al. Endoscopic management of biliary complications after adult living donor liver transplantation. Am J Gastroenterol 2004;99:1291-1295.
105. Fleck JA, Zanotelli ML, Meine M, Brandao A, Leipnitz I, Schlindwein E, et al. Biliary tract complications after orthotopic liver transplantation in adult patients. Transplant Proc 2002;34:519-520.
106. Chahin NJ, De Carlis L, Slim AO, Rossi A, Groeso CA, Rondinara GF, et al. Long-term efficacy of endoscopic stenting in patients with stricture of the biliary anastomosis after orthotopic liver transplantation. Transplant Proc 2001;33:2738-2740.
107. Zhou G, Cai W, Li H, Zhu Y, Fung JJ. Experiences relating to management of biliary tract complications following liver transplantation in 96 cases. Chin Med J 2002; 115:1533-1537.
108. Park JS, Kim MH, Lee SK, Seo DW, Lee SS, Han J, et al. Efficacy of endoscopic and percutaneous treatments for biliary complications after cadaveric and living donor liver transplantation. Gastrointest Endosc 2003;57:78-85.
109. Takatsuki M, Uemoto S, Inomata Y, Egawa H, Kiuchi T, Fujita S, et al. Weaning of immunosuppression in living donor liver transplant recipients [see comment]. Transplantation 2001;72:449-454.
110. Wiesner RH, Demetris AJ, Belle SH, Seaberg EC, Lake JR, Zetterman RK, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998;28:638-645.
111. Bak T, Wachs M, Trotter J, Everson G, Trouillot T, Kugelmas M, et al. Adult-to-adult living donor liver transplantation using right-lobe grafts: results and lessons learned from a single-center experience. Liver Transpl 2001;7:680-686.
112. Testa G, Malago M, Valentin-Gamazo C, Lindell G, Broelsch CE. Biliary anastomosis in living related liver transplantation using the right liver lobe: techniques and complications. Liver Transpl 2000;6:710-714.
113. Fan S-T, Lo C-M, Liu C-L, Yong B-H, Chan JK-F, Ng IO-L. Safety of donors in live donor liver transplantation using right lobe grafts. Arch Surg 2000;135:336-340.
114. Settmacher U, Theruvath T, Pascher A, Neuhaus P. Living-donor liver transplantation-European experiences. Nephrol Dial Transplant 2004;19(suppl 4):16-21.
115. Parolin MB, Lazzaretti CT, Lima JH, Freitas AC, Matias JE, Coelho JC. Donor quality of life after living donor liver transplantation. Transplant Proc 2004;36:912-913.
116. Ghobrial RM, Saab S, Lassman C, Lu DS, Raman S, Limanond P, et al. Donor and recipient outcomes in right lobe adult living donor liver transplantation. Liver Transpl 2002;8:901-909.
117. Malago M, Testa G, Frilling A, Nadalin S, Valentin-Gamazo C, Paul A, et al. Right living donor liver transplantation: an option for adult patients: single institution experience with 74 patients. Ann Surg 2003;238:853-862; discussion 862-853.
118. Garcia-Retortillo M, Forns X, Llovet JM, Navasa M, Feliu A, Massaguer A, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004;40:699-707.
119. Russo MW, Galanko J, Beavers K, Fried MW, Shrestha R. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl 2004;10:340-346.
120. Brown RS Jr. Is recurrence of hepatitis C worse after living donor or deceased donor liver transplantation? Liver Transpl 2004;10:1256.
121. Sugawara Y, Kaneko J, Akamatsu N, Kishi Y, Hata S, Kokudo N, et al. Living donor liver transplantation for end-stage hepatitis C. Transplant Proc 2004;36:1481-1482.
122. Rodriguez-Luna H, Vargas HE, Sharma P, Ortiz J, De Petris G, Balan V, et al. Hepatitis C virus recurrence in living donor liver transplant recipients. Dig Dis Sci 2004; 49:38-41.
123. Ohkubo M, Nagino M, Kamiya J, Yuasa N, Oda K, Arai T, et al. Surgical anatomy of the bile ducts at the hepatic hilum as applied to living donor liver transplantation. Ann Surg 2004;239:82-86.
124. Hisatsune H, Yazumi S, Egawa H, Asada M, Hasegawa K, Kodama Y, et al. Endoscopic management of biliary strictures after duct-to-duct biliary reconstruction in rightlobe living-donor liver transplantation. Transplantation 2003;76:810-815.
125. Taber DJ, Dupuis RE, Fann AL, Andreoni KA, Gerber DA, Fair JH, et al. Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients. Liver Transpl 2002;8:219-223.
126. Russo MW, Brown RS Jr. Is the cost of adult living donor liver transplantation higher than deceased donor liver transplantation? Liver Transpl 2004;10:467-468.
127. Longworth L, Bryan S. An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ 2003;12:1061-1067.
128. Walter M, Dammann G, Papachristou C, Pascher A, Neuhaus P, Danzer G, et al. Quality of life of living donors before and after living donor liver transplantation. Transplant Proc 2003;35:2961-2963.